Characterization of an in vitro-selected RNA ligand to the HIV-1 rev protein

A small RNA ligand with high affinity for the HIV-1 Rev protein, generated by the SELEX in vitro evolution method, was used in a series of chemical modification studies to aid in determining the secondary structure of the ligand, to detect which modifications interfere with the binding of the ligand...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of molecular biology 1994-01, Vol.235 (1), p.237-247
Hauptverfasser: Jensen, Kirk B., Green, Louis, MacDougal-Waugh, Sheela, Tuerk, Craig
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 247
container_issue 1
container_start_page 237
container_title Journal of molecular biology
container_volume 235
creator Jensen, Kirk B.
Green, Louis
MacDougal-Waugh, Sheela
Tuerk, Craig
description A small RNA ligand with high affinity for the HIV-1 Rev protein, generated by the SELEX in vitro evolution method, was used in a series of chemical modification studies to aid in determining the secondary structure of the ligand, to detect which modifications interfere with the binding of the ligand to Rev, and to find those modifiable groups that are protected from attack when bound to the Rev protein. This SELEX RNA ligand, like the high-affinity binding site of the Rev-responsive element, seems to bind the Rev protein within or along the major groove. There are two major regions of the RNA that interact with the Rev protein, and these regions appear to be close in space. Additionally, this high-affinity ligand has been used as the basis for an additional “biased randomization” SELEX procedure, in an effort to gain comprehensive information on the RNA sequences and structural elements necessary for efficient binding to the Rev protein. This complementary experimental approach supports the structural conclusions of our chemical modification data.
doi_str_mv 10.1016/S0022-2836(05)80030-0
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76333102</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022283605800300</els_id><sourcerecordid>16917308</sourcerecordid><originalsourceid>FETCH-LOGICAL-c420t-2207963dda908e1905b9d3429e514be3a292d84bf1d44415b7ad3f55497907713</originalsourceid><addsrcrecordid>eNqFkE1LJDEQhoMoOrr-BCEHEffQWvnqJCcZBleFYRfc1WtId6o10tOtSc-A_vptnWGunurwPm9V8RBywuCCASsv_wJwXnAjynNQPw2AgAJ2yISBsYUphdklky1yQA5zfgEAJaTZJ_uGG8ulmpD57NknXw-Y4ocfYt_RvqG-o7GjqzikvsjY4hgHev97Stv45LtAh54Oz0hv7x4LRhOu6GvqB4zdD7LX-Dbj8WYekYdf1_9mt8X8z83dbDovaslhKDgHbUsRgrdgkFlQlQ1CcouKyQqF55YHI6uGBSklU5X2QTRKSastaM3EETlb7x3vvi0xD24Rc41t6zvsl9npUgjBgH8LstIyLcCMoFqDdepzTti41xQXPr07Bu5Tt_vS7T5dOlDuS7eDsXeyObCsFhi2rY3fMT_d5D7Xvm2S7-qYt5gwxmrQI3a1xnC0toqYXK4jdjWGmEb7LvTxm0f-AwlrmKc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16917308</pqid></control><display><type>article</type><title>Characterization of an in vitro-selected RNA ligand to the HIV-1 rev protein</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Jensen, Kirk B. ; Green, Louis ; MacDougal-Waugh, Sheela ; Tuerk, Craig</creator><creatorcontrib>Jensen, Kirk B. ; Green, Louis ; MacDougal-Waugh, Sheela ; Tuerk, Craig</creatorcontrib><description>A small RNA ligand with high affinity for the HIV-1 Rev protein, generated by the SELEX in vitro evolution method, was used in a series of chemical modification studies to aid in determining the secondary structure of the ligand, to detect which modifications interfere with the binding of the ligand to Rev, and to find those modifiable groups that are protected from attack when bound to the Rev protein. This SELEX RNA ligand, like the high-affinity binding site of the Rev-responsive element, seems to bind the Rev protein within or along the major groove. There are two major regions of the RNA that interact with the Rev protein, and these regions appear to be close in space. Additionally, this high-affinity ligand has been used as the basis for an additional “biased randomization” SELEX procedure, in an effort to gain comprehensive information on the RNA sequences and structural elements necessary for efficient binding to the Rev protein. This complementary experimental approach supports the structural conclusions of our chemical modification data.</description><identifier>ISSN: 0022-2836</identifier><identifier>EISSN: 1089-8638</identifier><identifier>DOI: 10.1016/S0022-2836(05)80030-0</identifier><identifier>PMID: 8289245</identifier><identifier>CODEN: JMOBAK</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>AIDS/HIV ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Base Composition ; Base Sequence ; Biological and medical sciences ; Computer Graphics ; Consensus Sequence ; DNA-Directed RNA Polymerases - metabolism ; Gene Products, rev - metabolism ; HIV-1 - metabolism ; human immunodeficiency virus 1 ; Ligands ; Medical sciences ; Models, Molecular ; Molecular Sequence Data ; Nucleic Acid Conformation ; Oligodeoxyribonucleotides ; Pharmacology. Drug treatments ; protein-RNA interaction ; Rev ; rev Gene Products, Human Immunodeficiency Virus ; RNA ligand ; RNA, Viral - chemistry ; RNA, Viral - metabolism ; RRE ; SELEX ; Transcription, Genetic ; Viral Proteins</subject><ispartof>Journal of molecular biology, 1994-01, Vol.235 (1), p.237-247</ispartof><rights>1994 Academic Press Limited</rights><rights>1994 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c420t-2207963dda908e1905b9d3429e514be3a292d84bf1d44415b7ad3f55497907713</citedby><cites>FETCH-LOGICAL-c420t-2207963dda908e1905b9d3429e514be3a292d84bf1d44415b7ad3f55497907713</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0022283605800300$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=3889707$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8289245$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jensen, Kirk B.</creatorcontrib><creatorcontrib>Green, Louis</creatorcontrib><creatorcontrib>MacDougal-Waugh, Sheela</creatorcontrib><creatorcontrib>Tuerk, Craig</creatorcontrib><title>Characterization of an in vitro-selected RNA ligand to the HIV-1 rev protein</title><title>Journal of molecular biology</title><addtitle>J Mol Biol</addtitle><description>A small RNA ligand with high affinity for the HIV-1 Rev protein, generated by the SELEX in vitro evolution method, was used in a series of chemical modification studies to aid in determining the secondary structure of the ligand, to detect which modifications interfere with the binding of the ligand to Rev, and to find those modifiable groups that are protected from attack when bound to the Rev protein. This SELEX RNA ligand, like the high-affinity binding site of the Rev-responsive element, seems to bind the Rev protein within or along the major groove. There are two major regions of the RNA that interact with the Rev protein, and these regions appear to be close in space. Additionally, this high-affinity ligand has been used as the basis for an additional “biased randomization” SELEX procedure, in an effort to gain comprehensive information on the RNA sequences and structural elements necessary for efficient binding to the Rev protein. This complementary experimental approach supports the structural conclusions of our chemical modification data.</description><subject>AIDS/HIV</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral agents</subject><subject>Base Composition</subject><subject>Base Sequence</subject><subject>Biological and medical sciences</subject><subject>Computer Graphics</subject><subject>Consensus Sequence</subject><subject>DNA-Directed RNA Polymerases - metabolism</subject><subject>Gene Products, rev - metabolism</subject><subject>HIV-1 - metabolism</subject><subject>human immunodeficiency virus 1</subject><subject>Ligands</subject><subject>Medical sciences</subject><subject>Models, Molecular</subject><subject>Molecular Sequence Data</subject><subject>Nucleic Acid Conformation</subject><subject>Oligodeoxyribonucleotides</subject><subject>Pharmacology. Drug treatments</subject><subject>protein-RNA interaction</subject><subject>Rev</subject><subject>rev Gene Products, Human Immunodeficiency Virus</subject><subject>RNA ligand</subject><subject>RNA, Viral - chemistry</subject><subject>RNA, Viral - metabolism</subject><subject>RRE</subject><subject>SELEX</subject><subject>Transcription, Genetic</subject><subject>Viral Proteins</subject><issn>0022-2836</issn><issn>1089-8638</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1LJDEQhoMoOrr-BCEHEffQWvnqJCcZBleFYRfc1WtId6o10tOtSc-A_vptnWGunurwPm9V8RBywuCCASsv_wJwXnAjynNQPw2AgAJ2yISBsYUphdklky1yQA5zfgEAJaTZJ_uGG8ulmpD57NknXw-Y4ocfYt_RvqG-o7GjqzikvsjY4hgHev97Stv45LtAh54Oz0hv7x4LRhOu6GvqB4zdD7LX-Dbj8WYekYdf1_9mt8X8z83dbDovaslhKDgHbUsRgrdgkFlQlQ1CcouKyQqF55YHI6uGBSklU5X2QTRKSastaM3EETlb7x3vvi0xD24Rc41t6zvsl9npUgjBgH8LstIyLcCMoFqDdepzTti41xQXPr07Bu5Tt_vS7T5dOlDuS7eDsXeyObCsFhi2rY3fMT_d5D7Xvm2S7-qYt5gwxmrQI3a1xnC0toqYXK4jdjWGmEb7LvTxm0f-AwlrmKc</recordid><startdate>19940107</startdate><enddate>19940107</enddate><creator>Jensen, Kirk B.</creator><creator>Green, Louis</creator><creator>MacDougal-Waugh, Sheela</creator><creator>Tuerk, Craig</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TM</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>19940107</creationdate><title>Characterization of an in vitro-selected RNA ligand to the HIV-1 rev protein</title><author>Jensen, Kirk B. ; Green, Louis ; MacDougal-Waugh, Sheela ; Tuerk, Craig</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c420t-2207963dda908e1905b9d3429e514be3a292d84bf1d44415b7ad3f55497907713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1994</creationdate><topic>AIDS/HIV</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral agents</topic><topic>Base Composition</topic><topic>Base Sequence</topic><topic>Biological and medical sciences</topic><topic>Computer Graphics</topic><topic>Consensus Sequence</topic><topic>DNA-Directed RNA Polymerases - metabolism</topic><topic>Gene Products, rev - metabolism</topic><topic>HIV-1 - metabolism</topic><topic>human immunodeficiency virus 1</topic><topic>Ligands</topic><topic>Medical sciences</topic><topic>Models, Molecular</topic><topic>Molecular Sequence Data</topic><topic>Nucleic Acid Conformation</topic><topic>Oligodeoxyribonucleotides</topic><topic>Pharmacology. Drug treatments</topic><topic>protein-RNA interaction</topic><topic>Rev</topic><topic>rev Gene Products, Human Immunodeficiency Virus</topic><topic>RNA ligand</topic><topic>RNA, Viral - chemistry</topic><topic>RNA, Viral - metabolism</topic><topic>RRE</topic><topic>SELEX</topic><topic>Transcription, Genetic</topic><topic>Viral Proteins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jensen, Kirk B.</creatorcontrib><creatorcontrib>Green, Louis</creatorcontrib><creatorcontrib>MacDougal-Waugh, Sheela</creatorcontrib><creatorcontrib>Tuerk, Craig</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of molecular biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jensen, Kirk B.</au><au>Green, Louis</au><au>MacDougal-Waugh, Sheela</au><au>Tuerk, Craig</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Characterization of an in vitro-selected RNA ligand to the HIV-1 rev protein</atitle><jtitle>Journal of molecular biology</jtitle><addtitle>J Mol Biol</addtitle><date>1994-01-07</date><risdate>1994</risdate><volume>235</volume><issue>1</issue><spage>237</spage><epage>247</epage><pages>237-247</pages><issn>0022-2836</issn><eissn>1089-8638</eissn><coden>JMOBAK</coden><abstract>A small RNA ligand with high affinity for the HIV-1 Rev protein, generated by the SELEX in vitro evolution method, was used in a series of chemical modification studies to aid in determining the secondary structure of the ligand, to detect which modifications interfere with the binding of the ligand to Rev, and to find those modifiable groups that are protected from attack when bound to the Rev protein. This SELEX RNA ligand, like the high-affinity binding site of the Rev-responsive element, seems to bind the Rev protein within or along the major groove. There are two major regions of the RNA that interact with the Rev protein, and these regions appear to be close in space. Additionally, this high-affinity ligand has been used as the basis for an additional “biased randomization” SELEX procedure, in an effort to gain comprehensive information on the RNA sequences and structural elements necessary for efficient binding to the Rev protein. This complementary experimental approach supports the structural conclusions of our chemical modification data.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>8289245</pmid><doi>10.1016/S0022-2836(05)80030-0</doi><tpages>11</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0022-2836
ispartof Journal of molecular biology, 1994-01, Vol.235 (1), p.237-247
issn 0022-2836
1089-8638
language eng
recordid cdi_proquest_miscellaneous_76333102
source MEDLINE; Elsevier ScienceDirect Journals
subjects AIDS/HIV
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Base Composition
Base Sequence
Biological and medical sciences
Computer Graphics
Consensus Sequence
DNA-Directed RNA Polymerases - metabolism
Gene Products, rev - metabolism
HIV-1 - metabolism
human immunodeficiency virus 1
Ligands
Medical sciences
Models, Molecular
Molecular Sequence Data
Nucleic Acid Conformation
Oligodeoxyribonucleotides
Pharmacology. Drug treatments
protein-RNA interaction
Rev
rev Gene Products, Human Immunodeficiency Virus
RNA ligand
RNA, Viral - chemistry
RNA, Viral - metabolism
RRE
SELEX
Transcription, Genetic
Viral Proteins
title Characterization of an in vitro-selected RNA ligand to the HIV-1 rev protein
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T07%3A16%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Characterization%20of%20an%20in%20vitro-selected%20RNA%20ligand%20to%20the%20HIV-1%20rev%20protein&rft.jtitle=Journal%20of%20molecular%20biology&rft.au=Jensen,%20Kirk%20B.&rft.date=1994-01-07&rft.volume=235&rft.issue=1&rft.spage=237&rft.epage=247&rft.pages=237-247&rft.issn=0022-2836&rft.eissn=1089-8638&rft.coden=JMOBAK&rft_id=info:doi/10.1016/S0022-2836(05)80030-0&rft_dat=%3Cproquest_cross%3E16917308%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16917308&rft_id=info:pmid/8289245&rft_els_id=S0022283605800300&rfr_iscdi=true